NCT07764588

Brief Summary

To determine the relationship of the phenotypes of neutrophils and monocytes with early fibrotic repair after acute myocardial infarction.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
50

participants targeted

Target at P25-P50 for all trials

Timeline
4mo left

Started Jan 2026

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress62%
Jan 2026Dec 2026

Study Start

First participant enrolled

January 1, 2026

Completed
7 months until next milestone

First Submitted

Initial submission to the registry

August 10, 2026

Completed
4 days until next milestone

First Posted

Study publicly available on registry

August 14, 2026

Completed
5 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 31, 2026

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2026

Last Updated

August 14, 2026

Status Verified

August 1, 2026

Enrollment Period

12 months

First QC Date

August 10, 2026

Last Update Submit

August 12, 2026

Conditions

Myocardial Infarction

Keywords

neutrophilmonocytemyocardial infarctioncardiac remodelingcardiac magnetic resonance

Outcome Measures

Primary Outcomes (1)

  • Major cardiac adverse outcome

    The composite endpoint included cardiac death, non-fatal myocardial infarction, and rehospitalization for angina.

    At 12 months after enrollment

Secondary Outcomes (1)

  • Cardiac remodeling measured by CMR

    At 1 week after admission

Study Arms (1)

STEMI patients

Patients with acute STEMI within 12 hours of symptom onset receive primary percutaneous coronary intervention.

Eligibility Criteria

Age18 Years - 80 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

STEMI patients undergoing PPCI

You may qualify if:

  • \---- Age \> 18 and ≤ 80 years old
  • \- Patients with acute STEMI within 12 hours of symptom onset who are planned to receive PPCI

You may not qualify if:

  • Prior revascularization
  • Known allergy to gadopentetate dimeglumine contrast agent
  • Pregnancy or planned pregnancy within the next 6 months
  • Life expectancy \< 1 year
  • Metallic implants or claustrophobia that precluded MRI
  • Severe COPD or inability to hold breath for MRI
  • Severe hepatic or renal dysfunction (ALT \> 5×ULN or eGFR \< 15 mL/min/1.73 m²)

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Shanghai Tenth People's Hospital

Shanghai, China

RECRUITING

Biospecimen

Retention: SAMPLES WITHOUT DNA

Peripheral blood will be collected for phenotypes of innate immune cells by flow cytometry and sequencing.

MeSH Terms

Conditions

Myocardial Infarction

Condition Hierarchy (Ancestors)

Myocardial IschemiaHeart DiseasesCardiovascular DiseasesVascular DiseasesInfarctionIschemiaPathologic ProcessesPathological Conditions, Signs and SymptomsNecrosis

Central Study Contacts

Jianhui Zhuang, MD

CONTACT

86-13621742833jh_zhuang@tongji.edu.cn

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Consultant

Study Record Dates

First Submitted

August 10, 2026

First Posted

August 14, 2026

Study Start

January 1, 2026

Primary Completion (Estimated)

December 31, 2026

Study Completion (Estimated)

December 31, 2026

Last Updated

August 14, 2026

Record last verified: 2026-08

Locations

CN(1)